What happened
Jason Hulse Murray sold 45,707 PACS Group, Inc. shares from 2026-10-19 to 2026-10-21 under a Rule 10b5-1 plan. The Form 4 lists Murray as Co-Founder, CEO & Chairman, a director and a 10% owner, and shows common stock sales on each of the three dates.
The reported prices ran from $47.57 to $47.65 per share, and the filing puts the total value at about $2.18 million. Murray still held 54,270,813 shares after the final sale.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 45,707 shares | SEC Form 4 | |
| Total sale value | about $2.18 million | SEC Form 4 | |
| Sale price range | $47.57 to $47.65 per share | SEC Form 4 | |
| Shares held after sale | 54,270,813 shares | SEC Form 4 |
Read more: PACS Group (PACS) stock analysis and investment case
Why it matters
The filing is an ownership update, not an operating update, and the plan date matters because it shows the sales were prearranged on 2026-05-18. The 45,707 shares amount to about 0.1% of Murray's pre-trade holding, so the sale trims the stake but does not alter the ownership picture in a material way.
Murray's remaining 54,270,813 shares show a large continuing position after the three-day sale. The filing also shows sales on 2026-10-19, 2026-10-20 and 2026-10-21, which lets investors match the transaction to one reported plan rather than a sudden open-market exit.
OptimistFi's case is that PACS can compound if its independently operated facility model keeps turning post-acute demand into profitable cash flow despite labor, reimbursement and regulatory pressure. This filing leaves that thesis unchanged because the sale was pre-set under Rule 10b5-1 and Murray still held 54,270,813 shares. The caveat is that the Form 4 is still a material insider-ownership update, so investors may track whether future filings show larger changes in the stake.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
PACS Group's next quarterly report is the next scheduled check on operating performance and ownership. A stronger report would matter more to the case than this plan-based sale, while a weaker one would carry more weight than the Form 4. Until that filing arrives, this disclosure stands as a completed insider transaction with a defined sale range, a set plan date and a remaining stake that is still large.
More from OptimistFi
- PACS stock: the PACS Group thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
Sources
- SEC Form 4 — PACS Group, Inc. Form 4 for Jason Hulse Murray's common stock sales on 2026-10-19 to 2026-10-21.
Read the full OptimistFi thesis on PACS Group, Inc.: https://optimistfi.com/stocks/PACS
See what would break the PACS Group, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full PACS Group, Inc. investment case, its status and the next test to watch live on the PACS Group, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
